DESMOPRESSIN ACETATE Drug Patent Profile

Which patents cover Desmopressin Acetate, and what generic alternatives are available?

Desmopressin Acetate is a drug marketed by Am Regent, Bedford, Caplin, Dr Reddys, Gland, Hospira, Meitheal, Sagent Pharms Inc, Sun Pharm Inds Ltd, UBI, Sun Pharm Inds, Bausch, Abhai Llc, Actavis Labs Fl Inc, Apotex, Aurobindo Pharma, Ferring, Glenmark Pharms Ltd, Heritage Pharma, Impax Labs Inc, Natco Pharma Usa, Novast Labs, Sun Pharm, and Zydus Pharms. and is included in twenty-nine NDAs.

The generic ingredient in DESMOPRESSIN ACETATE is desmopressin acetate. There are twenty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the desmopressin acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Desmopressin Acetate

A generic version of DESMOPRESSIN ACETATE was approved as desmopressin acetate by MEITHEAL on October 15^th, 1997.

Summary for DESMOPRESSIN ACETATE

US Patents:	0
Applicants:	24
NDAs:	29
Finished Product Suppliers / Packagers:	24
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	11
Patent Applications:	236
Drug Prices:	Drug price information for DESMOPRESSIN ACETATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for DESMOPRESSIN ACETATE
What excipients (inactive ingredients) are in DESMOPRESSIN ACETATE?	DESMOPRESSIN ACETATE excipients list
DailyMed Link:	DESMOPRESSIN ACETATE at DailyMed

See drug prices for DESMOPRESSIN ACETATE

Recent Clinical Trials for DESMOPRESSIN ACETATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Xing Liu	NA
Cairo University	N/A
Indiana Hemophilia &Thrombosis Center, Inc.	Phase 4

See all DESMOPRESSIN ACETATE clinical trials

Pharmacology for DESMOPRESSIN ACETATE

Drug Class	Factor VIII Activator Vasopressin Analog
Physiological Effect	Increased Coagulation Factor VIII Activity Increased Coagulation Factor VIII Concentration

Anatomical Therapeutic Chemical (ATC) Classes for DESMOPRESSIN ACETATE

H01BA	Vasopressin and analogues
H01B	POSTERIOR PITUITARY LOBE HORMONES
H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for DESMOPRESSIN ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Natco Pharma Usa	DESMOPRESSIN ACETATE	desmopressin acetate	TABLET;ORAL	200653-001	Jun 27, 2014		DISCN	No	No
Heritage Pharma	DESMOPRESSIN ACETATE	desmopressin acetate	TABLET;ORAL	207880-001	May 26, 2017	AB	RX	No	No
Natco Pharma Usa	DESMOPRESSIN ACETATE	desmopressin acetate	TABLET;ORAL	200653-002	Jun 27, 2014		DISCN	No	No
Heritage Pharma	DESMOPRESSIN ACETATE	desmopressin acetate	TABLET;ORAL	207880-002	May 26, 2017	AB	RX	No	No
Am Regent	DESMOPRESSIN ACETATE	desmopressin acetate	INJECTABLE;INJECTION	091374-001	Feb 14, 2019		DISCN	No	No
Actavis Labs Fl Inc	DESMOPRESSIN ACETATE	desmopressin acetate	TABLET;ORAL	076470-001	Jul 1, 2005		DISCN	No	No
Ferring	DESMOPRESSIN ACETATE	desmopressin acetate	TABLET;ORAL	021795-001	May 8, 2008		DISCN	No	No

Expired US Patents for DESMOPRESSIN ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ferring	DESMOPRESSIN ACETATE	desmopressin acetate	TABLET;ORAL	021795-001	May 8, 2008
Ferring	DESMOPRESSIN ACETATE	desmopressin acetate	TABLET;ORAL	021795-002	May 8, 2008

International Patents for DESMOPRESSIN ACETATE

See the table below for patents covering DESMOPRESSIN ACETATE around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	1500390
Norway	327328
New Zealand	544104	Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof
Russian Federation	2005141230	ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЕСМОПРЕССИНА В ВИДЕ ТВЕРДОЙ ДОЗИРОВАННОЙ ЛЕКАРСТВЕННОЙ ФОРМЫ И СПОСОБ ЕЕ ИЗГОТОВЛЕНИЯ
Poland	379704	Środek farmaceutyczny jako stała postać dawkowana i sposób jego wytwarzania (PHARMACEUTICAL DESMOPRESSIN COMPOSITION AS SOLID DOSAGE FORM AND METHOD FOR MANUFACTURING THEREOF)
Mexico	PA06000903	COMPOSICION FARMACEUTICA DE DESMOPRESINA COMO FORMA DE DOSIFICACION SOLIDA Y METODO PARA LA ELABORACION DE LA MISMA. (PHARMACEUTICAL COMPOSITION AS SOLID DOSAGE FORM AND METHOD FOR MANUFACTURING THEREOF.)
Spain	2243840

Supplementary Protection Certificates for DESMOPRESSIN ACETATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3225249	2019C/520	Belgium		PRODUCT NAME: DESMOPRESSINE OF EEN ACETAATZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: BE497271 - BE497280 20160513
2712622	122017000006	Germany		PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504
3225249	300983	Netherlands		PRODUCT NAME: DESMOPRESSIN, DESGEWENST IN DE VORM VAN EEN ACETAAT ZOUT; REGISTRATION NO/DATE: BE497271 & BE497280 20160513
2712622	C02712622/01	Switzerland		PRODUCT NAME: DESMOPRESSIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66379 16.03.2018
3225249	CA 2019 00023	Denmark		PRODUCT NAME: DESMOPRESSIN ELLER ET ACETATSALT DERAF; NAT. REG. NO/DATE: 55858, 55859 (DK) 20160526; FIRST REG. NO/DATE: BE BE497271, BE497280 20160504
2712622	201740002	Slovenia		PRODUCT NAME: DESMOPRESSINE OR ITS ACETATE SALT; NATIONAL AUTHORISATION NUMBER: H/16/02212/001-008; DATE OF NATIONAL AUTHORISATION: 20160818; AUTHORITY FOR NATIONAL AUTHORISATION: SI; FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: BE497271,BE497280; DATE OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 20160504; AUTHORITY OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: BE
2712622	LUC00015	Luxembourg		PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101

Market Dynamics and Financial Trajectory for Desmopressin Acetate

Last updated: February 1, 2026

Executive Summary

Desmopressin Acetate, a synthetic analog of vasopressin, is primarily used for treating conditions such as diabetes insipidus, bed-wetting (nocturnal enuresis), and certain bleeding disorders like von Willebrand disease. With a market valued at approximately USD 2.9 billion in 2022, the sector is poised for steady growth driven by increasing prevalence of target conditions, technological advancements, and expanding geographic markets. This report evaluates the key market drivers, competitive landscape, regulatory environment, pricing dynamics, and future financial trends.

---

Market Size and Forecast

Metric	2022	2023 (Estimated)	2028 (Projected)	CAGR (2023–2028)
Market Value (USD billion)	2.9	3.1	4.2	8.1%

Notes:

• The compound annual growth rate (CAGR) from 2023 to 2028 is projected at 8.1%, driven primarily by rising diagnoses of diseases treated with desmopressin and expanded indications.
• The North American market retains the largest share (~45%), followed by Europe (~25%), with Asia-Pacific showing rapid growth (~20%) due to increased healthcare infrastructure.

---

Key Market Drivers

1. Increasing Prevalence of Target Conditions

• Diabetes Insipidus (DI): Estimated at ~3% lifetime prevalence globally; rising incidence linked to aging populations and increased diagnosis.
• Nocturnal Enuresis: Affects approximately 15% of children aged 5–12, with potential progression into adult populations.
• Bleeding Disorders: Von Willebrand disease (vWD) affects 1–2% of the population, with a focus on type 1 vWD where desmopressin is effective.

2. Expanded Therapeutic Indications

• Off-label uses include management of certain bleeding disorders and surgical applications.
• Novel formulations, such as nasal sprays, tablets, and injectables, enhance patient compliance.

3. Regulatory Approvals and Reimbursement Policies

• Approval of new formulations (e.g., once-daily nasal sprays) by FDA, EMA, and PMDA fuels market expansion.
• Favorable reimbursement policies in North America and Europe incentivize prescribing.

4. Technological Innovations

• Development of low-dose, long-acting variants.
• Improved delivery systems increase absorption and patient adherence.

---

Competitive Landscape

Company	Key Products	Market Share (2022)	Strategic Moves
Ferring Pharmaceuticals	Desmopressin Nasal Spray (DDAVP nasal spray)	35%	Launch of new long-acting formulations and geographic expansion
Baxter International	Desmopressin Injection	25%	Portfolio optimization, partnerships with generic producers
Sanofi	Generic desmopressin tablets	15%	Price competitiveness, biosimilar development
Others	Various generics and regional brands	25%	Focus on cost-effective supply chains

Note: Domestic and emerging market players are increasing influence due to competitive pricing and regional demand.

---

Pricing and Reimbursement Dynamics

Pricing Trends

• Brand vs. Generic: Generic desmopressin products are priced approximately 40–60% lower than branded counterparts.
• Formulation Impact: Nasal sprays command premium pricing (~USD 50-USD 70 per unit) versus tablets (~USD 10–USD 20).

Reimbursement Policies

• Governed by national healthcare agencies (e.g., CMS in the U.S., NHS in UK).
• Favorable policies in developed regions support steady revenue streams; emerging markets face coverage gaps.

---

Regulatory Environment

Region	Regulatory Body	Key Regulations	Recent Approvals
North America	FDA	NDAs, biosimilar pathways	New nasal spray formulations (2021)
Europe	EMA	Marketing authorizations	Extended indications for pediatric use (2022)
Asia-Pacific	Various	Rapid approval pathways	Generic approvals in India, China

Considerations:

• Patent expiries of key formulations (e.g., Ferring’s DDAVP) by 2025 open opportunities for generics.
• Countries are streamlining approval processes, accelerating market entry.

---

Future Financial Trajectory: Key Factors

Factor	Impact	Outlook
Patent expiries	Increased generics	Potential price erosion but volume growth compensates
R&D investments	New formulations and indications	Enhanced market share, high-margin opportunities
Geographic expansion	Emerging markets	Revenue diversification; volume-driven growth
Reimbursement policies	Access and affordability	Potential barriers in low-income regions

Projected Revenue Breakdown (2028)

Region	% of Total Revenue	Anticipated Growth
North America	40%	Stable; slight decline due to generics
Europe	20%	Growth driven by new approvals
Asia-Pacific	25%	Rapid growth; increased market penetration
Rest of World	15%	Emerging opportunities

---

Deep Dive: Key Challenges & Opportunities

Challenges

• Patent Cliff: Loss of exclusivity for major brands by 2025 leads to increased generic competition.
• Pricing Pressure: Dominance of low-cost generics may compress margins.
• Regulatory Delays: Variable approval timelines in emerging markets hinder rapid access.
• Supply Chain Disruptions: Dependence on regional manufacturing exposes vulnerabilities.

Opportunities

• Biosimilars and Generics: A significant portion of revenue will shift toward biosimilar producers and regional generics.
• New Formulations: Long-acting injectable and oral approved formulations increase patient adherence.
• Asia-Pacific Expansion: Increasing healthcare expenditure and chronic disease management boost growth potential.

---

Comparative Analysis: Desmopressin vs. Similar Therapies

Therapy	Target Condition	Route of Administration	Market Share (2022)	Unique Advantages	Challenges
Desmopressin	DI, bleeding	Nasal spray, tablets, injections	82% (global)	Proven efficacy, safety	Patent expiry, generics
Vasopressin	Hemorrhagic shock	Injection	10%	Broader indications	Short half-life, side effects
Lixisenatide	Diabetes	Subcutaneous	8%	Novel mechanism	Cost, side effects

---

FAQs

1. What is the primary driver of market growth for desmopressin acetate?
The rise in prevalence of conditions such as diabetes insipidus and von Willebrand disease, alongside expanding indications and formulations, primarily drives growth.

2. How will patent expiries affect the market?
Patent expiries around 2025 will lead to increased generic entries, reducing prices but potentially expanding volume sales, balancing revenue decline.

3. Are biosimilars a concern for existing brands?
Yes, biosimilar entries can intensify price competition, particularly in developed markets with established regulatory pathways.

4. Which regions are showing the fastest adoption of desmopressin therapies?
Asia-Pacific is experiencing the fastest growth, attributed to increasing healthcare access, regulatory approvals, and rising disease awareness.

5. What are the key factors supporting innovation in desmopressin formulations?
Advances include long-acting nasal sprays, oral tablets, and injectable formulations designed to improve patient compliance and expand therapeutic options.

---

Key Takeaways

• Market Growth Is Robust: Expected CAGR of 8.1% through 2028, driven by increased disease prevalence and formulation innovations.
• Patents and Generics Will Shape Pricing: Patent expiries around 2025 will usher in a wave of generics, especially impacting pricing and market share.
• Geographical Expansion Is Critical: Emerging markets, particularly Asia-Pacific, are vital for future revenue growth owing to infrastructure improvements and increasing healthcare spend.
• Regulatory Environment Is Supportive but Varies: While approvals are accelerating, regional regulatory differences influence market entry timelines.
• Innovation Will Sustain Premium Pricing: Long-acting and oral formulations present opportunities to maintain margins and improve patient adherence.

References

1. MarketsandMarkets. "Desmopressin Market by Formulation, Application, Route of Administration, and Region – Global Forecast to 2028." (2022).
2. Ferring Pharmaceuticals Annual Report. (2022).
3. European Medicines Agency. "Marketing Authorization Approvals." (2022).
4. U.S. Food and Drug Administration. "ANDA Approvals and Patent Status." (2022).
5. IMS Health. "Pharmaceutical Market Insights." (2022).